Asymmetrex Presents New Developments in its Rapid Stem Cell Counting Technology at the ARMI|BioFabUSA Meeting in the Millyard on Regenerative Medicine Biomanufacturing
Retrieved on:
Thursday, June 9, 2022
BOSTON, June 9, 2022 /PRNewswire-PRWeb/ -- In 2021, stem cell biotechnology company Asymmetrex announced its award of a Technical Project grant from ARMI|BioFabUSA. ARMI assembles, integrates, and leads academic, government, and industry partners in coordinated research and development with a unique vision of accelerating innovation in the biomanufacturing of products and treatments for regenerative medicine. Asymmetric became a member company of ARMI|BioFabUSA less than a year before being selected to evaluate whether its unique tissue stem cell counting technology could be successfully adapted for use in cell and tissue biomanufacturing.
Key Points:
- For the past year, with R&D funding support from the Advanced Regenerative Manufacturing Institute|BioFabUSA, stem cell biotechnology company Asymmetrex has been automating and adapting its tissue stem cell counting technology for use in cell and tissue biomanufacturing.
- Asymmetric became a member company of ARMI|BioFabUSA less than a year before being selected to evaluate whether its unique tissue stem cell counting technology could be successfully adapted for use in cell and tissue biomanufacturing.
- The facility and speed of the rapid stem cell counting algorithms enable straightforward integration of KSC counting for monitoring therapeutic stem cells in cell and tissue biomanufacturing processes.
- Asymmetrex markets kinetic stem cell (KSC) counting, the first technology for determination of the dose and quality of tissue stem cell preparations for use in stem cell transplantation medicine and pre-clinical drug evaluations.